Research programme: thrombin inhibiting aptamers - Oruka Therapeutics/Archemix
Alternative Names: ARC-2172Latest Information Update: 03 Sep 2024
At a glance
- Originator Archemix Corporation
- Developer Oruka Therapeutics
- Class Nucleotide aptamers
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Thrombosis